Eurofins Scientific SE (LON:0MV5)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 12.50B +37.5% |
| Revenue (ttm) | 6.36B +3.4% |
| Net Income | 404.62M +22.5% |
| EPS | 2.14 +28.9% |
| Shares Out | n/a |
| PE Ratio | 34.28 |
| Forward PE | 18.69 |
| Dividend | 0.63 (0.86%) |
| Ex-Dividend Date | Apr 28, 2026 |
| Volume | 31,324 |
| Open | 87.62 |
| Previous Close | 87.52 |
| Day's Range | 87.16 - 88.42 |
| 52-Week Range | 56.24 - 89.24 |
| Beta | 0.81 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Jan 29, 2027 |
About Eurofins Scientific SE
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product tes... [Read more]
Financial Performance
In 2025, Eurofins Scientific SE's revenue was 7.30 billion, an increase of 4.96% compared to the previous year's 6.95 billion. Earnings were 416.10 million, an increase of 16.78%.
Financial numbers in EUR Financial StatementsNews
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific price target raised to EUR 87.50 from EUR 73.70 at Citi
Citi raised the firm’s price target on Eurofins Scientific (ERFSF) to EUR 87.50 from EUR 73.70 and keeps a Neutral rating on the shares.
Eurofins Scientific SE Earnings Call Transcript: Q3 2026
Organic growth is below this year’s objective, but management expects mid-single-digit growth in 2027 and reaffirmed profit-improvement plans. Digital and laboratory investments, alongside cleanup actions, are intended to support growth and margins; delayed clinical programs and European weakness remain uncertainties.
Eurofins Scientific SE Earnings release: Q3 2026
Eurofins Scientific SE released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Eurofins Scientific SE Slides: Q3 2026
Eurofins Scientific SE has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 21, 2026.
Eurofins Scientific SE: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing F...
Eurofins Scientific downgraded to Market Perform from Outperform at Bernstein
Bernstein analyst Delphine Le Louet downgraded Eurofins Scientific (ERFSF) to Market Perform from Outperform with a EUR 73.90 price target The firm sees “structurally weaker” outlook for Eurofins amid...
Eurofins Scientific upgraded at Morgan Stanley
Morgan Stanley analyst Annelies Vermeulen upgraded Eurofins Scientific (ERFSF) with a price target of EUR 64.50, down from EUR 68.50. The company’s organic below is below the levels needed to…
Eurofins Scientific SE : Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (Paris:ERF) (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific price target raised to EUR 68.50 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eurofins Scientific (ERFSF) to EUR 68.50 from EUR 67.50 and keeps an Equal Weight rating on the shares.
Eurofins Scientific SE Earnings Call Transcript: Q2 2026
Strong H1 2026 results featured 29% EPS growth and margin expansion, driven by operational efficiencies, portfolio focus, and disciplined capital allocation. Despite Biopharma softness, guidance for mid-single-digit organic growth and margin improvement is reaffirmed.
Eurofins Scientific SE Earnings release: Q2 2026
Eurofins Scientific SE released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Eurofins Scientific SE Slides: Q2 2026
Eurofins Scientific SE has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Eurofins Scientific SE Quarterly report: Q2 2026
Eurofins Scientific SE has published its Q2 2026 quarterly earnings report on July 23, 2026.
Eurofins Scientific SE: Weekly Report on Share Repurchases from 13th July to 17th July 2026
LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins Scientific SE (Paris:ERF): Weekly report on share repurchases from 13th July to 17th July 2026 Name of the Issuer Identify code of the Issuer T...
CORRECTING and REPLACING: Eurofins Scientific: Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--This replaces the announcement made on 16 June 2026 due to the following correction: updated number of stock options exercised. The updated release reads: EUROFINS SCIENTI...
Eurofins Scientific SE Earnings Call Transcript: Q1 2026
Q1 revenue growth was hampered by severe weather, but March rebounded to mid-single digits. Management maintains full-year mid-single-digit organic growth guidance and expects continued margin improvement, supported by digitalization and portfolio optimization.
Eurofins Scientific SE Earnings release: Q1 2026
Eurofins Scientific SE released its Q1 2026 earnings on April 22, 2026, summarizing the period's financial results.
Eurofins Scientific SE Slides: Q1 2026
Eurofins Scientific SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 22, 2026.
UL Solutions to acquire Eurofins Scientific’s E&E business
UL Solutions (ULS) announced it has entered into a definitive agreement to acquire the electrical and electronics business of Eurofins Scientific SE (ERFSF). “Our technical talent, global accreditatio...
Eurofins Scientific : Director/PDMR Shareholding
LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) (Paris:ERF) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification ...
Eurofins Scientific price target raised to EUR 73.70 from EUR 63.50 at Citi
Citi raised the firm’s price target on Eurofins Scientific (ERFSF) to EUR 73.70 from EUR 63.50 and keeps a Neutral rating on the shares.
Eurofins Scientific SE Earnings Call Transcript: Q4 2025
Strong 2025 performance with all objectives met or exceeded, driven by margin expansion, robust EPS and free cash flow growth, and accelerating organic revenue. Major investments in IT and site ownership are nearing completion, supporting future growth and operational efficiency. Continued share buybacks and M&A are expected, with biopharma and core segments poised for recovery and expansion.
Eurofins Scientific SE Annual report: Q4 2025
Eurofins Scientific SE has published its Q4 2025 annual report on January 29, 2026.